HK IPOAI

TENNOR THERAP-B

0687218AListed

醫療健康 · TenNor Therapeutics是一家专注于创新药物研发的中国生物制药公司。

TENNOR THERAP-B (丹諾醫藥-B) (06872) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.

Offer price
HK$75.70
Final offer price
HK$75.70
One-lot win rate
0.8%

Predicted 1.7%

Proceeds
HK$670.4M
Public oversub.
9015.1x

Lot / entry fee 50 shares · HK$4K · Sponsor CITIC Securities / ABCI Capital

  1. Offer starts May 14
  2. /Offer closes May 19
  3. /Grey market May 21
  4. /Listing May 22Now

SubscriptionTENNOR THERAP-B: subscription-stage reference

The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.

Earlier stage
Reference rating
High attention
Reference score
75
Forecast grey range
+17.5% – +162.4%

Pre-greyTENNOR THERAP-B: pre-grey-market reference

The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.

Earlier stage
Reference rating
High attention
Reference score
79.5
Forecast grey range
+18.0% – +163.0%

Post-greyTENNOR THERAP-B: post-grey-market reference

The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.

Current
Reference rating
High attention
Reference score
82.9
Forecast first-day range
+90.3% – +158.4%
View factors and research
Model forecastListing-day trendStrong positiveUp probability 97.6%
Published outcome check
First-day resultBig up+178.7%
Our call: Trend call valid
Covered 16/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heat
Offer size
Good quality
Cornerstone lockup
Post-lockup offer value
Recent same-rule trend
Strong trend
Recent same-type trend
Strong trend
Recent sector trend
Strong trend
Valuation
Average appeal
Fundamental quality
Average quality
Growth quality
Profitability
Weak quality
Cash runway
Weak quality
Customer concentration
Cornerstone quality
Sponsor record
Strong record
Greenshoe arrangementGreenshoe: yes · 15%
Average support
Stabilizer track recordCLSA
Strong record
A-share pre-grey trend
A-share listing-day trend
Public oversubscription
High heat
One-lot win rate
High heat
International placing
High heat
Final pricing position
Actual greenshoe use
Grey market return
Strong trend

The assessment and probability ranges are informational only and are not investment advice.

AI Research Report

Post-grey
The analysis report for this IPO is being generated.

Last updated 18:35:03

HK$145.60
+92.34%
153.99110.6567.31HK$75.7016:1518:35
Listing price
HK$75.70
Open
High
Low
Bid / Ask
— / —
Volume
Turnover View source

TENNOR THERAP-B: predicted allotment

Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.

1 lot
1.7%

Official 0.8%

A tail · Apply 1,200 lots
0.1 lots

Official 0.14 lots

B head · Apply 1,400 lots
0.1 lots

Official 0.14 lots

Top hammer
0.34 lots

Official 0.44 lots

Most likely allotment patternLarger Pool A applications get less extra allotmentPool B allotment declines gradually with sizeView full allotment-odds research

How to read this page

These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.

What is the one-lot allotment rate for TENNOR THERAP-B?

Public allotment filings put the official one-lot rate at 0.8%, versus this site's pre-allotment model estimate of 1.7%. It is an observation for a 1-lot application, not a guaranteed result.

What is the difference between A-tail and B-head for TENNOR THERAP-B?

Based on the prospectus's legal application tiers, A-tail is 1,200 lots and B-head is 1,400 lots, representing about HK$4.5M and HK$5.3M of application principal. Official average allotment was 0.14 lots and 0.14 lots, versus pre-allotment model estimates of 0.1 lots and 0.1 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.

Can the grey-market price of TENNOR THERAP-B be treated as the listing price?

The compiled grey-market observation is about +93.3%, versus +178.7% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.

Why does TENNOR THERAP-B have three reference ratings?

The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.